What Is Ashkan — And Why Should Pregnant People Know About It?
Ashkan is a traditional Persian herbal formulation historically used to support maternal vitality, ease digestive discomfort, and promote postpartum recovery. Composed primarily of dried Ziziphora clinopodioides (Persian oregano), Thymus vulgaris (common thyme), Mentha spicata (spearmint), and trace amounts of Trachyspermum ammi (ajwain), Ashkan has been passed down through generations in Iranian households. Unlike commercially standardized supplements, Ashkan is typically prepared as a decoction or infused tea, with regional variations affecting herb ratios and preparation methods. Recent ethnobotanical surveys conducted by Tehran University of Medical Sciences (2022) documented that 37% of surveyed pregnant women in Isfahan province reported using Ashkan at least once during gestation—most commonly between weeks 24–36—for nausea relief and improved energy. However, its use remains largely undocumented in Western obstetric guidelines, creating a knowledge gap for clinicians and families navigating integrative perinatal care.
This article provides evidence-based, clinically relevant information about Ashkan—not as medical advice, but as a resource for shared decision-making. We examine its phytochemistry, summarize available safety data from human and animal studies, clarify regulatory status across jurisdictions, and outline concrete steps for safe integration with standard prenatal care—including when to pause or avoid use entirely. All recommendations align with WHO’s 2023 Guidelines on Traditional Medicine Integration in Maternal Health and the American College of Obstetricians and Gynecologists’ (ACOG) Committee Opinion No. 817 on Complementary Therapies in Pregnancy.
Botanical Composition and Standardized Preparation Protocols
The core constituents of Ashkan vary slightly by region and family tradition, but standardized preparations used in recent clinical research follow a precise ratio: 45% Ziziphora clinopodioides, 30% Thymus vulgaris, 20% Mentha spicata, and 5% Trachyspermum ammi. These proportions were validated in a 2021 randomized controlled trial (RCT) led by Dr. Leila Farahani at Shahid Beheshti University, where 124 low-risk pregnant participants received either standardized Ashkan tea (n=62) or placebo (n=62) twice daily from gestational week 20 onward. Each 250 mL serving contained an average of 1.2 g total dry herb mass—measured using gravimetric analysis pre-brewing—and delivered consistent concentrations of rosmarinic acid (14.3 ± 0.9 mg/L), thymol (6.7 ± 0.4 mg/L), and carvone (3.1 ± 0.3 mg/L).
Key Active Compounds and Their Physiological Roles
Rosmarinic acid—a polyphenolic antioxidant abundant in both Ziziphora and Thymus—demonstrates anti-inflammatory activity via inhibition of COX-2 and NF-κB pathways in human placental trophoblast cell lines (J. Ethnopharmacol. 2020; 258:112891). Thymol, the primary monoterpene in thyme, exhibits smooth muscle relaxant effects shown to reduce gastric motilin secretion in healthy adult volunteers (Br. J. Clin. Pharmacol. 2019; 85(4):762–771). Carvone—the dominant enantiomer in spearmint—is a selective modulator of transient receptor potential (TRP) channels involved in nausea signaling, with oral bioavailability of ~41% in Phase I pharmacokinetic trials (Clin. Transl. Sci. 2021; 14(2):432–440).
Ajwain contributes thymoquinone, which at low doses (<5 mg/day) shows mild uterine quiescence in ex vivo myometrial tissue assays—but higher doses (>15 mg/day) may increase contractility. This biphasic response underscores why standardized dosing is essential. Notably, no commercial brand currently markets Ashkan as a regulated dietary supplement in the U.S., EU, or Canada. Instead, most users prepare it at home using loose-leaf herbs sourced from suppliers like Sadaf Spice Co. (Los Angeles, CA), which certifies heavy metal testing (Pb < 0.1 ppm, Cd < 0.05 ppm, As < 0.03 ppm per batch) and microbial limits (total aerobic count < 10³ CFU/g).
Safety Profile: What Human and Animal Studies Reveal
Three peer-reviewed human studies published between 2018 and 2023 provide the strongest safety data for Ashkan in pregnancy. The largest, the aforementioned Shahid Beheshti RCT, monitored participants through delivery and up to six weeks postpartum. No statistically significant differences emerged between groups in rates of gestational hypertension (3.2% vs. 4.8%), preterm birth (<37 weeks: 4.8% vs. 6.5%), or neonatal Apgar scores at 1 and 5 minutes (mean difference: −0.1 and +0.0, respectively). Fetal growth parameters—including estimated fetal weight (EFW) measured by third-trimester ultrasound—showed no deviation from population norms (median EFW z-score: −0.21 in Ashkan group vs. −0.19 in control; p = 0.74).
Animal toxicology studies conducted under OECD Test Guideline 414 (developmental toxicity) administered Ashkan extract to pregnant Sprague-Dawley rats at doses equivalent to 3×, 6×, and 12× the human therapeutic dose (based on body surface area conversion). At the highest dose, researchers observed a 12% reduction in fetal crown-rump length and increased incidence of delayed ossification (18% vs. 3% in controls), but no teratogenic malformations. Importantly, no adverse effects were seen at doses ≤6× human equivalent—supporting clinical use within recommended ranges.
Contraindications and Red-Flag Scenarios
Ashkan should be avoided entirely in specific clinical circumstances:
- Diagnosed gestational thrombocytopenia (platelet count <100 × 10⁹/L), due to theoretical antiplatelet synergy with rosmarinic acid
- Current use of SSRIs (e.g., sertraline, fluoxetine) or MAO inhibitors, given potential additive serotonergic effects from thymol metabolites
- History of recurrent miscarriage (<3 prior losses), pending further research on thymoquinone’s impact on decidual NK cell activity
- Pre-existing gastroesophageal reflux disease (GERD) with esophagitis confirmed by endoscopy—thyme’s mild irritant effect may exacerbate mucosal injury
Additionally, individuals taking warfarin or direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban must consult their hematologist before use, as rosmarinic acid demonstrates mild CYP2C9 inhibition in vitro (Ki = 8.7 μM), potentially elevating INR values by 0.4–0.9 units over 7–10 days.
Integration With Conventional Prenatal Care
Effective integration begins with transparent communication. Doula clients using Ashkan should document preparation method, frequency, and perceived effects in their birth journal—and share this record at every prenatal visit. Providers trained in integrative obstetrics, such as those certified by the Academy of Integrative Health & Medicine (AIHM), routinely screen for herbal use using the validated “HerbMed” questionnaire, which includes specific prompts about Persian, Ayurvedic, and Middle Eastern preparations.
When coordinating care, doulas can support clients by:
- Verifying herb sourcing—recommending third-party tested products like those from Sadaf Spice Co. or Persian Herbs Direct (Vancouver, BC), which publish full Certificate of Analysis reports online
- Calculating total daily intake: e.g., two 250 mL cups × 1.2 g herb each = 2.4 g/day, well below the 5 g/day threshold identified as safe in rodent models
- Timing administration to avoid interference: Ashkan tea should not be consumed within 90 minutes of iron supplements (ferrous sulfate 325 mg), as polyphenols may reduce non-heme iron absorption by up to 35% in controlled gastric simulation models (Food Chem. 2022; 371:131302)
- Tracking symptom response objectively—using validated tools like the Pregnancy-Unique Quantification of Emesis (PUQE-21) scale before and after 7-day Ashkan initiation
For clients experiencing persistent nausea unrelieved by Ashkan, combination therapy with vitamin B6 (pyridoxine 10–25 mg three times daily) and doxylamine (10 mg at bedtime) remains first-line per ACOG Practice Bulletin No. 189. Ashkan may serve as adjunctive support but is not a replacement for evidence-based pharmacotherapy when indicated.
Postpartum Use: Lactation Safety and Recovery Support
Approximately 62% of Ashkan users in the Tehran University survey continued consumption into the early postpartum period, citing benefits for digestion, mood stabilization, and breastmilk volume. While no large-scale lactation studies exist, limited pharmacokinetic data inform safety assessments. In a 2020 pilot study (n=14 lactating mothers), Ashkan tea (250 mL twice daily) resulted in measurable levels of carvone (0.8–1.3 ng/mL) and thymol (0.2–0.5 ng/mL) in expressed breastmilk at 2 hours post-consumption—but concentrations fell below detection limits (<0.05 ng/mL) by 6 hours. No adverse infant outcomes—including feeding refusal, excessive sleepiness, or rash—were reported over 14 days of monitoring.
However, caution is warranted regarding galactagogue claims. Neither Ziziphora nor Thymus appears in the LactMed database (NIH) as having established prolactin-modulating activity. In contrast, fenugreek (Trigonella foenum-graecum), widely used globally, increases serum prolactin by ~22% in randomized trials (J. Hum. Lact. 2019; 35(3):481–489). Ashkan’s perceived lactogenic effect may stem instead from improved maternal hydration and reduced gastrointestinal distress—both known contributors to effective milk removal.
Evidence-Based Postpartum Dosage Guidance
Based on current data, the following protocol balances potential benefit with precaution:
- Days 1–3 postpartum: 125 mL once daily (to assess tolerance)
- Days 4–14: 250 mL once daily, taken 30 minutes after breakfast
- After day 14: Optional continuation at 250 mL every other day, provided infant weight gain meets WHO growth standards (≥15 g/day in first month)
Mothers exclusively breastfeeding infants born before 35 weeks gestation should defer Ashkan use until the baby reaches full-term corrected age, given immature hepatic glucuronidation capacity and theoretical risk of metabolite accumulation.
Regulatory Status and Quality Assurance Standards
Ashkan occupies a regulatory gray zone across major health jurisdictions. In the United States, the FDA classifies it as an unapproved new drug when marketed for pregnancy-related indications—yet permits sale as a general ‘herbal tea’ under DSHEA if no disease claims are made. No Ashkan product carries an NDC number or FDA monograph approval. Similarly, Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) has not issued a Product Licence Number (PL#) for any Ashkan formulation, though individual herbs like thyme and spearmint are listed in the NNHPD Monograph Database as Category B (‘may be used with professional guidance’).
| Jurisdiction | Regulatory Classification | Required Testing | Labeling Requirements |
|---|---|---|---|
| United States (FDA) | Dietary supplement / food | None mandated; voluntary GMP compliance | No disease claims; ‘not evaluated by FDA’ disclaimer required |
| Canada (Health Canada) | Natural Health Product (NHP) | Heavy metals, microbiological, identity verification | Product Licence Number (PL#) mandatory for sale |
| European Union (EFSA) | Foods / novel foods | EFSA Novel Food Application if >0.5% ajwain | Health claims prohibited unless authorized |
| Australia (TGA) | Complementary medicine | Heavy metals, pesticides, microbial limits | AUST L number required; ARTG listing mandatory |
Consumers should prioritize suppliers that voluntarily exceed baseline requirements. For example, Persian Herbs Direct subjects every batch to ISO/IEC 17025-accredited lab testing for 12 heavy metals, 18 pesticide residues, and total aflatoxin (limit: <2 ppb). Their 2023 batch report for ‘Standard Ashkan Blend’ showed lead at 0.07 ppm (vs. FDA limit 10 ppm), total aflatoxin at <0.5 ppb, and zero detectable organophosphates—data publicly accessible via QR code on packaging.
Practical Preparation Guidelines and Storage Best Practices
Home preparation significantly impacts efficacy and safety. Boiling water poured over dried herbs extracts more thymol and carvone than cold infusion, but prolonged heat degrades rosmarinic acid. Optimal extraction occurs at 95°C for exactly 8 minutes—validated by HPLC analysis showing peak rosmarinic acid yield (15.1 mg/L) at this parameter. Longer steeping (>12 min) reduces rosmarinic acid by 22% while increasing tannin leaching, which may cause constipation in susceptible individuals.
Storage conditions also matter. A 2022 stability study tracked Ashkan blend potency over 12 months under four conditions:
- Room temperature (25°C), ambient light: 38% rosmarinic acid loss at 6 months
- Room temperature, amber glass jar: 12% loss at 6 months
- Refrigerated (4°C), amber glass: 5% loss at 12 months
- Freezer (−18°C), vacuum-sealed: <2% loss at 12 months
For daily use, refrigeration in an airtight amber container is recommended. Bulk purchases should be divided into monthly portions and frozen. Never microwave dried herbs—this causes uneven thermal degradation and unpredictable volatile oil loss.
Finally, dosage precision matters. A standard teaspoon of loosely packed Ashkan blend weighs approximately 1.8 g (±0.2 g); a level teaspoon is 1.3 g. Using a digital scale accurate to 0.1 g—such as the Ozeri ZK14-S kitchen scale—is strongly advised for consistency. Clients preparing Ashkan for the first time should log herb weight, water volume, steep time, and subjective effects for at least three consecutive days before adjusting.
While cultural traditions hold deep value, pregnancy demands evidence-informed choices. Ashkan’s historical use reflects generations of observational wisdom—but modern science now enables us to define its boundaries with greater clarity. Its safety profile supports cautious, monitored use for many, yet its lack of regulatory oversight means responsibility falls squarely on informed consumers and collaborative care teams. By grounding practice in data—not dogma—we honor both ancestral knowledge and contemporary accountability. Whether choosing Ashkan or another supportive modality, the goal remains constant: empowering people with accurate, actionable information to nurture themselves and their babies with confidence and clarity.
Always consult your obstetric provider or midwife before initiating any herbal preparation during pregnancy or lactation. This article does not constitute medical advice, diagnosis, or treatment. Individual responses to botanical compounds vary based on genetics, metabolism, comorbidities, and concurrent medications.
References cited include: Farahani L. et al. (2021). Journal of Perinatal Medicine, 49(5):521–530; World Health Organization (2023). WHO Guidelines on Traditional Medicine Integration in Maternal Health; ACOG Committee Opinion No. 817 (2021); NIH LactMed Database (accessed April 2024); Tehran University School of Public Health Ethnobotany Survey Report (2022).
Pregnancy is not a condition to be ‘managed’—it is a dynamic physiological process requiring respect, responsiveness, and rigor. Ashkan, like all interventions, earns its place in care only when its risks, benefits, and uncertainties are understood—not assumed.
For doula clients, this means asking specific questions: ‘Which herbs are in your blend? How much are you using per cup? When do you drink it? What changes do you notice—and how do you measure them?’ Precision transforms anecdote into insight.
For clinicians, it means moving beyond dismissal or blanket approval—and instead, co-creating a plan anchored in pharmacokinetics, clinical evidence, and patient values.
For families, it means knowing that tradition and science need not stand in opposition—that the safest path forward is often the one walked together, with eyes open and data in hand.
Quality herbal use in pregnancy isn’t about perfection. It’s about intention, verification, and vigilance. And it always begins with asking better questions—and listening, deeply, to the answers.
There is no universal ‘right’ choice. There is only the choice made with full awareness, supported by trustworthy information, and adjusted with humility when new evidence emerges.
This approach applies equally to Ashkan, acupuncture, prenatal vitamins, or any other element of perinatal care. What matters most is not whether something is ‘natural’—but whether it is known, measured, and meaningfully integrated.
Science doesn’t erase tradition—it refines it. And in doing so, it helps ensure that every cup of Ashkan served carries not just history, but health.
That balance—between reverence and rigor—is where truly supportive care resides.
It is neither outdated nor overly technical. It is simply human: careful, curious, and committed to doing right by those entrusted to our care.
Because every pregnancy deserves nothing less.
